CN100584329C - 茴三硫软胶囊及其制备方法 - Google Patents
茴三硫软胶囊及其制备方法 Download PDFInfo
- Publication number
- CN100584329C CN100584329C CN200710198877A CN200710198877A CN100584329C CN 100584329 C CN100584329 C CN 100584329C CN 200710198877 A CN200710198877 A CN 200710198877A CN 200710198877 A CN200710198877 A CN 200710198877A CN 100584329 C CN100584329 C CN 100584329C
- Authority
- CN
- China
- Prior art keywords
- anethol trithione
- soft capsule
- oil
- trithione
- anethol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001074 1-methoxy-4-[(E)-prop-1-enyl]benzene Substances 0.000 title claims abstract description 156
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 title claims abstract description 156
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 title claims abstract description 156
- 239000007901 soft capsule Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims description 37
- 239000000375 suspending agent Substances 0.000 claims abstract description 50
- 229920000136 polysorbate Polymers 0.000 claims abstract description 32
- 239000003921 oil Substances 0.000 claims abstract description 30
- 235000019198 oils Nutrition 0.000 claims abstract description 30
- 239000000758 substrate Substances 0.000 claims abstract description 30
- 239000004094 surface-active agent Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003549 soybean oil Substances 0.000 claims abstract description 17
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 17
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 15
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 12
- 240000008415 Lactuca sativa Species 0.000 claims abstract description 8
- 235000012045 salad Nutrition 0.000 claims abstract description 8
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 claims abstract description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims abstract description 4
- 239000004006 olive oil Substances 0.000 claims abstract description 4
- 235000008390 olive oil Nutrition 0.000 claims abstract description 4
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 46
- 239000000843 powder Substances 0.000 claims description 30
- 239000007766 cera flava Substances 0.000 claims description 27
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 27
- 239000008158 vegetable oil Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000000080 wetting agent Substances 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 22
- 239000013530 defoamer Substances 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 16
- -1 Oleum Helianthi Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 7
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical group 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000007765 cera alba Substances 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 4
- 238000000227 grinding Methods 0.000 claims 1
- 235000019482 Palm oil Nutrition 0.000 abstract description 21
- 239000002540 palm oil Substances 0.000 abstract description 21
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 239000001993 wax Substances 0.000 abstract 2
- 229910002012 Aerosil® Inorganic materials 0.000 abstract 1
- 240000002791 Brassica napus Species 0.000 abstract 1
- 235000006008 Brassica napus var napus Nutrition 0.000 abstract 1
- 229920000742 Cotton Polymers 0.000 abstract 1
- 235000019483 Peanut oil Nutrition 0.000 abstract 1
- 235000013871 bee wax Nutrition 0.000 abstract 1
- 239000012166 beeswax Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002285 corn oil Substances 0.000 abstract 1
- 235000005687 corn oil Nutrition 0.000 abstract 1
- 239000000312 peanut oil Substances 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- 229930193551 sterin Natural products 0.000 abstract 1
- 235000020238 sunflower seed Nutrition 0.000 abstract 1
- 229940045860 white wax Drugs 0.000 abstract 1
- 239000011550 stock solution Substances 0.000 description 30
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 28
- 229920000053 polysorbate 80 Polymers 0.000 description 28
- 238000004090 dissolution Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 11
- 239000008347 soybean phospholipid Substances 0.000 description 11
- 230000000857 drug effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 235000019580 granularity Nutrition 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 239000003240 coconut oil Substances 0.000 description 6
- 235000019864 coconut oil Nutrition 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 238000005464 sample preparation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
超微粉成分 | 软胶囊基质 | 体外溶出度 | |
处方一 | 无 | 聚乙二醇 | 53% |
处方二 | 无 | 植物油 | 8% |
处方三 | 茴三硫 | 聚乙二醇 | 82% |
处方四 | 茴三硫 | 植物油 | 23% |
处方五 | 茴三硫+SDS-Na | 聚乙二醇 | 95% |
处方六 | 茴三硫+SDS-Na | 植物油 | 21% |
处方七 | 茴三硫+乳糖 | 聚乙二醇 | 91% |
处方八 | 茴三硫+乳糖 | 植物油 | 16% |
处方九 | 茴三硫+乳糖+SDS-Na | 聚乙二醇 | 97% |
处方十 | 茴三硫+乳糖+SDS-Na | 植物油 | 20% |
处方 | 内容物基质 | 与片剂比较的相对生物利用度 |
处方一 | 聚乙二醇 | 53%±14.1% |
处方二 | 植物油 | 26%±21.6% |
处方四 | 植物油 | 47%±23.4% |
处方九 | 聚乙二醇 | 59%±18.7% |
处方 | 表面活性剂 | 润湿剂 | 溶出度 | 与片剂比较相对生物利用度 |
上市片剂 | --- | --- | 76% | 100% |
处方一 | 吐温-80 | ---- | 97% | 141%±13.6% |
处方二 | 吐温-80 | 大豆磷脂 | 105% | 156%±11.9% |
茴三硫 | 司盘 | 卖泽 | 蔗糖棕榈酸酯p=1670 | 聚氧乙烯氢化蓖麻油 | 溶出度 | |
处方1 | 25g | 10% | ---- | ----- | ---- | 69% |
处方2 | 25g | 20% | ---- | ----- | ---- | 64% |
处方3 | 25g | ----- | 10% | ---- | ----- | 57% |
处方4 | 25g | ----- | 20% | ---- | ----- | 61% |
处方5 | 25g | ---- | ----- | 5% | ---- | 56% |
处方6 | 25g | ---- | ----- | 10% | ---- | 54% |
处方7 | 25g | ---- | ---- | ---- | 5% | 62% |
处方8 | 25g | ---- | ---- | ---- | 10% | 66% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710198877A CN100584329C (zh) | 2007-12-19 | 2007-12-19 | 茴三硫软胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710198877A CN100584329C (zh) | 2007-12-19 | 2007-12-19 | 茴三硫软胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101204393A CN101204393A (zh) | 2008-06-25 |
CN100584329C true CN100584329C (zh) | 2010-01-27 |
Family
ID=39565022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710198877A Active CN100584329C (zh) | 2007-12-19 | 2007-12-19 | 茴三硫软胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100584329C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103211856B (zh) * | 2013-05-03 | 2014-07-23 | 李成仁 | 一种可以解酒的油类混合物 |
CN108853051B (zh) * | 2018-09-04 | 2020-12-18 | 安士制药(中山)有限公司 | 一种熊去氧胆酸软胶囊及其制备方法 |
FR3087445B1 (fr) * | 2018-10-19 | 2021-12-17 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Composition lipidique pour l'encapsulation d'une substance active et permettant le controle de la vitesse de liberation de ladite substance active |
-
2007
- 2007-12-19 CN CN200710198877A patent/CN100584329C/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101204393A (zh) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070009559A1 (en) | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same | |
DE60014162T2 (de) | Fenofibrathaltige galenische arzneizusammensetzungen und verfahren zu ihrer herstellung | |
US20020103139A1 (en) | Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control | |
TW202114701A (zh) | 一種含有醋酸阿比特龍的藥物組合物及其製備方法和應用 | |
NO336917B1 (no) | Butylftalid selvemulgerende medikamentavgivelsessystem, samt fremgangsmåter for fremstilling og anvendelse av samme | |
CN100386082C (zh) | 谷维素组合物及其制备方法 | |
EP1249230B1 (de) | Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen | |
CN105395492A (zh) | 一种挥发油固体自乳化片剂及其制备方法 | |
CN105617133A (zh) | 复合牡丹籽油自乳化体系组合物及其制备方法 | |
CN100584329C (zh) | 茴三硫软胶囊及其制备方法 | |
CN101810576B (zh) | 一种基于混合油的葛根素自微乳组合物及其制备方法 | |
CN107921017A (zh) | 使用卡多曲组合物进行治疗的方法 | |
CN101103962A (zh) | 长春西汀口服自微乳化释药系统及其制备方法 | |
CN103405385A (zh) | 一种替莫唑胺静脉注射脂肪乳及其制备方法 | |
CN105919949B (zh) | 一种稳定的氟比洛芬酯冻干乳及其制备方法 | |
CN102470121B (zh) | 包含决奈达隆的药物组合物 | |
US11344598B2 (en) | Herbal nanoformulations for treating psoriasis and other skin conditions | |
CN101011373A (zh) | 一种含左卡尼汀的药物组合物及其制备方法 | |
RU2353350C2 (ru) | Усовершенствованная система доставки лекарств | |
CN105708911A (zh) | 牡丹籽油自乳化体系组合物及其制备方法 | |
CN102727793B (zh) | 一种益坤宁药物组合物固体脂质纳米粒制剂 | |
CN103284953B (zh) | 一种双环醇固体制剂及其制备方法 | |
CN101199602B (zh) | 一种治疗妇科疾病的含药软胶囊及其制备方法 | |
JP5036114B2 (ja) | テルビナフィン含有医薬組成物 | |
CN101401788B (zh) | 联苯双酯自乳化制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YAO JUNHUA Effective date: 20120307 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120307 Address after: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee after: Jiaosu Wangao Pharmaceutical Co., Ltd. Address before: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee before: Yao Junhua |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee after: Jiangsu Wangao Pharmaceutical Co., Ltd. Address before: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee before: Jiaosu Wangao Pharmaceutical Co., Ltd. |